US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Militia Long/Short Equity ETF

29.50

+0.39001.34%

Post-market: 29.500.00000.00%16:00 EDT

Volume:23.63K

Turnover:696.09K

Market Cap:- -

PE:- -

High:29.71

Open:29.71

Low:29.30

Close:29.11

Loading ...

Overview Company News Filings

IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer…

Zacks Small Cap Research

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

Press Release: InnoCare Releases 2024 Results and Business Highlights

CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Press Release: CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress

Press Release: ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

Press Release: Immatics Announces Full Year 2024 Financial Results and Business Update

Press Release: Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

Third Eurostar challenger steps up

Elevation Oncology Plunges 42% on Ending Development of Lead Drug

Press Release: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ORR/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":29.5,"timestamp":1751054400000,"preClose":29.11,"halted":0,"volume":23629,"hourTrading":{"tag":"盘后","latestPrice":29.5,"preClose":29.5,"latestTime":"16:00 EDT","volume":15,"amount":442.5,"timestamp":1751054402295},"delay":0,"floatShares":2870000,"shares":0,"eps":0,"marketStatus":"Market Closed","change":0.39,"latestTime":"06-27 16:00:00 EDT","open":29.71,"high":29.71,"low":29.3,"amount":696091.5463,"amplitude":0.014085,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":29.11,"sharesOutstanding":2870000,"nav":29.02,"aum":83287400,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":29.22,"preClose":29.09,"latestTime":"09:28 EDT","volume":60,"amount":1753.1999999999998,"timestamp":1751030924719},"postHourTrading":{"tag":"盘后","latestPrice":29.5,"preClose":29.5,"latestTime":"16:00 EDT","volume":15,"amount":442.5,"timestamp":1751054402295},"volumeRatio":1.0280451084091622},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":2870000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.0280451084091622,"shares":0,"dividePrice":0,"high":29.71,"amplitude":0.014085,"preClose":29.11,"low":29.3,"week52Low":25.63,"pbRate":"--","week52High":29.71,"institutionHeld":0,"latestPrice":29.5,"eps":0,"divideRate":0,"volume":23629,"delay":0,"ttmEps":0,"open":29.71,"prevYearClose":25.88,"prevWeekClose":28.65,"prevMonthClose":28.1031,"prevQuarterClose":27.84,"fiveDayClose":28.65,"twentyDayClose":28.2522,"sixtyDayClose":27.92},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523840506","title":"IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer…","url":"https://stock-news.laohu8.com/highlight/detail?id=2523840506","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523840506?lang=en_us&edition=fundamental","pubTime":"2025-03-28 22:19","pubTimestamp":1743171540,"startTime":"0","endTime":"0","summary":"On March 24, 2025, Imunon, Inc.  announced it reached alignment with the U.S. FDA on the protocol for a Phase 3 clinical trial, referred to as OVATION 3, of its lead candidate IMNN-001 for the treatment of women with newly diagnosed advanced ovarian cancer. Trial sites are currently being initiated with the first patient to be enrolled in the near term.The following slide provides the overall design of the trial. Eligible patients will have either Stage IIIc and IV advanced ovarian cancer and will be randomized to receive neoadjuvant chemotherapy , interval debulking surgery, and adjuvant chemotherapy. Patients who are positive for homologous recombination deficiency  are also eligible and will receive poly ADP-ribose polymerase  inhibitor therapy as part of standard-of-care  maintenance therapy. The primary endpoint is overall survival , with secondary endpoints evaluating surgical response score, chemotherapy response score, clinical response , and time to second-line treatment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imnn-protocol-place-phase-3-141900552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4225","BK4097","SOC","HR","LU0054578231.USD","GSD","BK4213","ITT","BK4139","ORR","LU0053671581.USD","BK4161","BK4203","OS","IMNN"],"gpt_icon":0},{"id":"2522257316","title":"Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2522257316","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522257316?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:00","pubTimestamp":1743163200,"startTime":"0","endTime":"0","summary":"Recommendation is based primarily on results from the Phase 3 CheckMate -67T trial which demonstrated noninferiority in the co-primary endpoints of Cavgd28 and Cminss and consistent efficacy in the secondary endpoint of overall response rate for the subcutaneous formulation of Opdivo vs. its intravenous formulation. A decision on the EU Opdivo extension of marketing authorization is expected by June 2, 2025. \"The positive CHMP opinion is an important step forward in the evolution of immuno-oncology and in the potential of subcutaneous nivolumab to help transform the lives of people living with cancer,\" said Dana Walker, M.D., M.S.C.E., Opdivo global program lead, Bristol Myers Squibb. \"We look forward to bringing the same high-quality care that transformed cancer treatment with an administration method that has the potential to improve the patient experience and efficiency of healthcare systems in Europe.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-receives-positive-120000105.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1291159041.SGD","LU0096364046.USD","LU1670710661.SGD","UK","LU1261432733.SGD","BK4585","ORR","EEA","CRT","BK4007","LU0456855351.SGD","BMY","LU1670711040.USD","EC","IE00BJJMRZ35.SGD","LU0868494617.USD","IE0002141913.USD","BK4532","LU1074936037.SGD","LU1093756168.USD","LU2133065610.SGD","LU0237698245.USD","LU1718418525.SGD","LU1093756325.SGD","RCC","VOD","BK4500","LU0882574055.USD","BK4534","CHMP","IE00BFTCPJ56.SGD","ALK","LU1670711123.USD","BK4008","LU0061475181.USD","MYE","HSCT","LU1032466523.USD","LU0321505439.SGD","LU1868836914.USD","LU1670710588.SGD","LU2242652126.USD","LU1323610961.USD","IE0009355771.USD","BK4528","BK4559","BK4156","TEN","LU0306807586.USD"],"gpt_icon":0},{"id":"2522533947","title":"Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522533947","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522533947?lang=en_us&edition=fundamental","pubTime":"2025-03-28 02:27","pubTimestamp":1743100046,"startTime":"0","endTime":"0","summary":"The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ Tivdak  for advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy.Tivdak is the first and only antibody-drug conjugate  to be approved for cervical cancer in Japan.The approval is based on data from the Phase 3 innovaTV 301 clinical trial that evaluated the efficacy and safety of TIVDAK compared to chemotherapy in patients with advanced or recurrent cervical cancer who were previously treated with chemotherapy.Also Read: AbbVie/Genmab’s Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway. The trial included 502 patients, 101 of which were Japanese.Median OS was 11.5 months among patients treated with Tivdak compared to 9.5 months for patients who received chemotherapy. Secondary endpoints of progression-free survival  and confirmed objective response rate  were also met.This article Japanese Drug Regulator Approves Genmab","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/japanese-drug-regulator-approves-genmab-182726829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3B42.SGD","BK4592","BK4599","LU0289739699.SGD","IE00B19Z3581.USD","LU0321505439.SGD","SG9999001176.SGD","ADC","AEIS","IE00B66KJ199.SGD","BK4007","GMAB","LU0456855351.SGD","PFS","LU0306807586.USD","LU0321505868.SGD","IE0031619046.USD","SG9999001176.USD","LU1066051498.USD","LU1066053197.SGD","IE00B7SZL793.SGD","BK4534","SG9999013999.USD","LU0985481810.HKD","LU1883839398.USD","BK4568","LU0234572021.USD","LU0058720904.USD","LU1894683264.USD","BK4585","IE00B19Z4B17.USD","IE00BLSP4452.SGD","OS","BK4588","LU0225284248.USD","BK4533","IE00BBT3K403.USD","BK4550","BK4157","LU0170899867.USD","IE0002270589.USD","LU0122379950.USD","ORR","BK4211","IE000M9KFDE8.USD","IE00BLSP4239.USD","BK4195","LU1057294990.SGD","BK4139"],"gpt_icon":1},{"id":"2522305666","title":"Press Release: InnoCare Releases 2024 Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522305666","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522305666?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:08","pubTimestamp":1743080880,"startTime":"0","endTime":"0","summary":"InnoCare Pharma , a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2024 annual results as of 31 December 2024.-- Revenue of Orelabrutinib increased by 49.1% to RMB 1,000.4 million1 in. 2024, mainly driven by rapid growth of marginal zone lymphoma . indication and strong commercial execution. Total revenue increased by. -- Gross Profit increased by 42.8% to RMB 871.0 million in 2024, with a. gross profit margin of 86.3%, representing an increase of 3.7 percentage. in 2024, primarily due to increased investment in advanced technology. as of 31 December 2024. This robust cash position provides InnoCare with. InnoCare will continue to strengthen the globalization of its other promising pipeline assets. As part of its BD strategy, the Company has been actively exploring collaboration and licensing opportunities for key assets, with a focus on expanding its presence outside of China. The Company remains committed to accelerating the global r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","QD","TLS","5I4.SI","BK4503","BK4097","BK4166","BK6512","ORR","BK6004"],"gpt_icon":0},{"id":"2522708653","title":"CERo Therapeutics Holdings, Inc.  Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522708653","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522708653?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:15","pubTimestamp":1743077700,"startTime":"0","endTime":"0","summary":"Company reports acceptance of an abstract at the 2025 American Society of Clinical Oncology  conference; Continues to be on track to dose first patient in first half of 2025. SOUTH SAN FRANSCISCO, Calif., March 27, 2025  -- CERo Therapeutics Holdings, Inc.,   an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has received positive review from the U.S. Food and Drug Administration  on an amendment to its IND around Chemistry, Manufacturing and Controls , which marks completion of the Company’s final commitment to FDA prior to initiating patient dosing and shortens the manufacturing timeline by about a week. With this completion, the Company is on track to meet its anticipated timeline of dosing initial subjects during the first half of 2025.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the tr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-poised-121500919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0971096721.USD","CEROW","LU0882574139.USD","PK","BK4006","LU1363072403.SGD","CERO","BK4181","LU0170899867.USD","LU0267386448.USD","CMC","BK4161","ORR","IE00BKVL7J92.USD","CR","LU0149725797.USD","IE00B1BXHZ80.USD","IE00BHPRN162.USD","IE00BZ1G4Q59.USD","BK4218"],"gpt_icon":0},{"id":"2522305374","title":"TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2522305374","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522305374?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:00","pubTimestamp":1743076800,"startTime":"0","endTime":"0","summary":"TIVDAK is the first and only antibody-drug conjugate  approved for patients with advanced or recurrent cervical cancer in Japan. Approval is based on results from the global Phase 3 innovaTV 301 trial, in which TIVDAK demonstrated superior overall survival compared to chemotherapy. Rising cervical cancer incidence and mortality rates in Japan signify need for new treatment options. COPENHAGEN, Denmark, March 27, 2025----Genmab A/S  today announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK  for the treatment of advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. TIVDAK is the first and only ADC to be approved for people living with cervical cancer in Japan.In recent years, cervical cancer incidence and mortality rates have increased in Japan, particularly among women under age 50.i,ii,iii Moreover, patients with recurrent or metastatic cervical cancer whose disease has progressed after first-line therapy have limited","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tivdak-tisotumab-vedotin-approved-japan-120000054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BLSP4239.USD","SG9999001176.SGD","SGXZ57979304.SGD","BK4592","LU1066051498.USD","LU1894683348.USD","SG9999011175.SGD","SG9999003800.SGD","SG9999013999.USD","AEIS","L","BK4107","LU0122379950.USD","PN","LU0053666078.USD","LU0289739699.SGD","BK4097","GMAB","LU0058720904.USD","LU0868494617.USD","IE00B19Z3581.USD","BK4139","ADC","BK4157","BK4568","OS","BK4585","LU1883839398.USD","LU0170899867.USD","LU0321505868.SGD","BK4007","ORR","SG9999002224.SGD","IE0031619046.USD","LU0321505439.SGD","BK4550","PFS","LU0225284248.USD","BK4080","LU0306807586.USD","IE00B19Z4B17.USD","LU1057294990.SGD","IE0002270589.USD","IE000M9KFDE8.USD","LU0456855351.SGD","LU1066053197.SGD","BK4599","BK4533","SG9999002232.USD"],"gpt_icon":1},{"id":"2522374205","title":"Press Release: CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522374205","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522374205?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:55","pubTimestamp":1743076500,"startTime":"0","endTime":"0","summary":"-      Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income.-          EU & UK: Approved for first-line treatment of stage IV non-small cell lung cancer ; stage III NSCLC new indication application submitted to EMA.-     Global Partnerships: Three strategic partnerships across 40+ countries, to accelerate global commercialization.-      Localized Production: Approved for localized manufacturing in China, enhancing cost efficiency.-      Commercial Collaboration: Partnered with Hengrui to expand market access in China.-      Leading Position: Top 2 globally in clinical development for ROR1-targeted ADCs.-      Preclinical Differentiation: Superior tumor suppression vs. benchmarked competitors; potential first-in-class/best-in-class IO backbone therapy.-      More than 9 Differentiated Candidates: Focus on first-in-class/best-in-class assets, including multispecific antibodies and ADCs, with global rights and broad therapeutic potential.SUZHOU, Ch","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823414478.USD","LU1642822529.SGD","LU2249611893.SGD","LU0444973449.USD","PFS","02616","LU0957808578.USD","CDE","BK4541","CPS","R","BK4109","ASH","BK4210","PRGS","LU2065732104.USD","BK4231","BK4211","BK1161","LU0345780521.USD","LU0476273544.USD","LU2357125470.USD","BK4182","BK4097","ADC","BK1574","BK4080","LU0444971666.USD","LU0823414551.USD","LU2506951792.HKD","HL","LU2463526074.USD","SOC","BK4585","BK4588","BK4213","LU2294711713.HKD","OS","BK4232","BE","CEE","LU1815336760.USD","BK4570","BK4195","ORR","BK4022","BK4017","BK4124","SITC"],"gpt_icon":0},{"id":"2522379277","title":"Press Release: ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522379277","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522379277?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:30","pubTimestamp":1743075000,"startTime":"0","endTime":"0","summary":"ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update. Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate; data update expected in second quarter 2025. Completed enrollment in LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA plus rituximab in patients with 2L+ DLBCL; data update anticipated in late 2025 once PFS events reached. $250.9M in cash as of December 31, 2024, provides runway expected to fund operations into the second half of 2026. LAUSANNE, Switzerland, March 27, 2025 /PRNewswire/ -- ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates , today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent operational updates.Fourth Quarter 2024 Operational Updates and Upcoming Milestones. and the complete response rate  was 72%. Th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBD","BK4139","BK4022","BK4505","BK4094","LU2463526074.USD","BK4211","ADCT","ASH","BK4231","03160","BK4585","BK4080","BK4588","BK4099","R","ORR","FL","ADC","BK4195","BK4109","BK4232","BK4604","BK4555","PFS","TM","LENZ"],"gpt_icon":0},{"id":"2522537175","title":"Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2522537175","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522537175?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"Treatment with itolizumab did not improve complete or overall response rates at Day 29. Itolizumab achieved statistical significance in multiple secondary endpoints demonstrating compelling clinical benefit in longer-term outcomes, including complete response at Day 99, duration of complete response and failure-free survival. Breakthrough Therapy designation and meeting requests to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025. Management will host a conference call and webcast today at 8:30 am ET. \"The longer-term outcomes are important,\" said Dr. John Koreth, Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School. \"There are no approvals in first-line therapy for aGVHD, and no drug candidates have been able to demonstrate efficacy beyond four weeks. To demonstrate statistical significance in pre-specified endpoints of duration of complete response and failure-free survival, compared to standard of care therapy, is ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/equillium-announces-results-phase-3-110000303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CR","HST","BK4139","BK4585","EQ","ORR","BK4588","BK4218","BK4181","LU0054578231.USD","BK4161","ITT","BK4568","LU0053671581.USD"],"gpt_icon":0},{"id":"2522429371","title":"Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522429371","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522429371?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"Breakthrough Therapy designation and meeting request to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025. LA JOLLA, Calif., March 27, 2025----Equillium, Inc. , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2024, as well as corporate and clinical highlights.Announced topline data from the Phase 3 EQUATOR study in first-line acute graft-versus-host disease  demonstrating a favorable safety and tolerability profile, and clinically meaningful longer-term outcomes. There was no meaningful difference in complete response  and overall response rate  at Day 29 between itolizumab patients and placebo patients, but statistical significance and/or clinically meaningful benefit in longer term outcomes were achieved by itolizumab in the following measurements","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/equillium-reports-fourth-quarter-full-110000383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EQ","BK4139","BK4568","ORR","BK4161","CR"],"gpt_icon":0},{"id":"2522375178","title":"Press Release: Immatics Announces Full Year 2024 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375178","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375178?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"-- Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine. IMA203 TCR-T  in advanced melanoma patients; first patient. -- ACTengine IMA203 TCR-T : Phase 1b IMA203 data published in. October 2024 demonstrated a confirmed ORR of 54%, 12.1 months mDOR, 6. months mPFS and OS not reached at a mFU time of 8.6 months in advanced. melanoma patients; next data update on Phase 1b trial with extended. published in November 2024 showed enhanced pharmacology and potency,planned; next data update including ovarian cancer data planned in 2025. \"2025 will be marked by milestones across our TCR-T and TCR Bispecifics clinical portfolio, including advancing two of our main objectives for this year: firstly, reporting data on solid cancer types beyond melanoma, such as ovarian cancer, head and neck cancer and others and secondly, demonstrating that our next-generation, half-life extended TCR Bispecifics can deliver meaningful response rates in advanced solid cancer patients,\" said Harpreet Si","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","IMTX","BK4139","PFS","ORR","BK4195","BK4232","BK4211","BK4022"],"gpt_icon":0},{"id":"2522304123","title":"Press Release: Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522304123","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522304123?lang=en_us&edition=fundamental","pubTime":"2025-03-27 04:05","pubTimestamp":1743019500,"startTime":"0","endTime":"0","summary":"Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer . Topline data from registration-intent DENALI Part 2 anticipated by year end 2026. Strengthened management team to support execution of highly focused strategy. $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027. \"Zentalis reported significant progress in the development of azenosertib in 2024 and made important advancements this year. We plan to maintain strong execution on the late-stage development of azenosertib,\" said Julie Eastland, Chief Executive Officer of Zentalis. \"The clinical data we recently presented supports rapid advancement of azenosertib as a monotherapy therapy for patients with Cyclin E1+ PROC, and the continued development of azenosertib in other settings of ovarian cancer and other tumor types. With a sharpened focus on clinical developme","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4139","ORR","BK4232","PROC","BK4007","R","ZNTL","BK4022","BK4080","BK4231"],"gpt_icon":1},{"id":"2522455332","title":"Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522455332","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522455332?lang=en_us&edition=fundamental","pubTime":"2025-03-27 01:29","pubTimestamp":1743010151,"startTime":"0","endTime":"0","summary":"Leap Therapeutics, Inc. presented updated preliminary data on Wednesday from Part B of the DeFianCe Phase 2 trial of sirexatamab  in combination with bevacizumab and chemotherapy  compared to bevacizumab and chemotherapy .The trial enrolled patients with advanced microsatellite stable  colorectal cancer  who have received one prior systemic therapy for advanced disease.The updated analysis shared on Wednesday includes the overall response rate , an additional two months of patient follow-up for progression-free survival , and initial overall survival  data.As ofMarch 12, 2025, 34 patients remain on the study drug in the sirexatamab Experimental Arm compared to 24 patients in the Control Arm.In patients with highDKK1levels, the sirexatamab Experimental Arm has a statistically significant 32% higher ORR, 3.5 months longer PFS, and OS compared to the Control Arm:. In patients who had not received prior anti-VEGF therapy, the sirexatamab Experimental Arm has a statistically significant 22%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/penny-stock-leap-therapeutics-unveils-172911695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","CRC","LU0456854461.SGD","LPTX","ONC","BK4213","OS","BK4585","BK4195","BK4543","BK4139","BK4211","BK4505","IE00BMPRXR70.SGD","BK4113","BK4141","BK4588","ORR","BK4097","LU0348723411.USD","IE00BMPRXQ63.HKD","IE00BMPRXN33.USD","BK4563","LU0266512127.USD","MSS","BK4609","PFS"],"gpt_icon":1},{"id":"2522875506","title":"Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2522875506","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522875506?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:16","pubTimestamp":1742987760,"startTime":"0","endTime":"0","summary":"Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01. The VXM01-avelumab combination therapy was generally well-tolerated, with the majority of safety events being mild to moderate in severity. These safety and tolerability data are in-line with previously reported data onavelumab alone with no additional safety signals for the combination of VXM01 and avelumab.No serious adverse events were attributed to VXM01, while9 of 11  were related to the target disease, underscoring the well manageable safety profile of this combination therapy in a frail patient population.The reported safety and tolerability data, together with early indications for the potential relevance of a VXM01dependent, VEGFR-2 specific immune response in GBM therapy warrant further study.\"The completion of this Phase 2a study is a significant mi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/vaximm-ag-osr-company-announces-111600323.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vaximm-ag-osr-company-announces-111600323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","BK4097","OSRH","BK4139","ORR","BK4210","OSRHW","AG"],"gpt_icon":0},{"id":"2522187556","title":"Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522187556","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522187556?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:05","pubTimestamp":1742987100,"startTime":"0","endTime":"0","summary":"Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET. CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024.Reported positive updated data from Part B of the Phase 2 DeFianCe study of sirexatamab  in second-line patients with advanced microsatellite stable  colorectal cancer  confirming:. Statistically significant 22% higherORR and 2.6 month longer PFS in patients who had not had prior anti-VEGF therapy. FL-501 abstract accepted for poster presentation at the 2025 American Association for Cancer Research  Annual Meeting.Across the intent-to-treat population, thesirexatamab Experimental Arm had improved ORR compared to the Control Arm, with PFS and OS maturing with a higher number of patients continuing to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-reports-fourth-quarter-110500189.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-reports-fourth-quarter-110500189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PFS","BK4585","BK4563","BK4543","BK4195","LU0266512127.USD","BK4609","BK4588","ORR","BK4213","IE00BMPRXR70.SGD","BK4113","BK4141","BK4097","MSS","LU0456854461.SGD","IE00BMPRXQ63.HKD","OS","BK4211","CRC","LU0348723411.USD","LPTX","IE00BMPRXN33.USD","LENZ","BK4505"],"gpt_icon":1},{"id":"2522596875","title":"Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2522596875","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522596875?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:00","pubTimestamp":1742986800,"startTime":"0","endTime":"0","summary":"Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFSin second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy. Statistically significant 22% higher ORR and 2.6 month longer PFSin patients who had not had prioranti-VEGF therapy. Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET. \"The updated data from Part B of the DeFianCe study presented today confirms that sirexatamab can generate significantly higher ORR and longer PFS in CRC patients who have high levels of DKK1 or who have not had prior anti-VEGF therapy, two exploratory populations with strong scientific rationale. In the full intent-to-treat population, sirexatamab demonstrated a higher ORR and a tail population with longer PFS that continues to mature. With more sirexatamab-treated patients currently continuing on study drug than control arm patients, there is potential for the dataset to continue t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-reports-positive-updated-110000183.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-reports-positive-updated-110000183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","ARM","ORR","LU0456854461.SGD","LU0266512127.USD","LENZ","BK4141","BK4113","IE00BMPRXQ63.HKD","PFS","BK4543","BK4609","BK4588","BK4563","LPTX","LU0348723411.USD","BK4211","BK4213","BK4097","IE00BMPRXN33.USD","OS","MSS","BK4505","BK4195","BK4139","IE00BMPRXR70.SGD","CRC"],"gpt_icon":0},{"id":"2522837332","title":"New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings","url":"https://stock-news.laohu8.com/highlight/detail?id=2522837332","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522837332?lang=en_us&edition=fundamental","pubTime":"2025-03-26 07:02","pubTimestamp":1742943720,"startTime":"0","endTime":"0","summary":"SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or datopotamab deruxtecan-dlnk to TAGRISSO upon disease progression demonstrates strong clinical activity. WILMINGTON, Del., March 25, 2025----New study results presented at the European Lung Cancer Congress  2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO , as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated  non-small cell lung cancer . Highlights include:. LAURA Phase III trial of TAGRISSO in unresectable, Stage III EGFRm NSCLC after chemoradiotherapy  .SAVANNAH Phase II trial of TAGRISSO plus savolitinib in advanced EGFRm NSCLC with high levels of MET overexpression and/or amplification following disease progression on 1st-line TAGRISSO (#2O).FLAURA2 Phase III trial of TAGRISSO plus chemotherapy as 1st-line treatment for advanced EGFRm NSCLC .Professor Virginia Harrison, EGFR Positive UK, said: \"For people undergoin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/study-results-reinforce-tagrisso-osimertinib-230200995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","PFS","ORR","TEN","BK4007","LU0889565916.HKD","ADC","LU2236285917.USD","OS","BK4166","BK4503","QD","AZN","BK4231","BK4563","LU2417539215.USD","LU0109394709.USD","BK4213","BK4124","LU2456880835.USD","BK4568","BK4585","BK4211","LU1829250122.USD","LU2462157665.USD","LU0320765992.SGD","BK4588","BK4144","CRT","BK4097","EMM","BK4195"],"gpt_icon":1},{"id":"2521277524","title":"Third Eurostar challenger steps up","url":"https://stock-news.laohu8.com/highlight/detail?id=2521277524","media":"cityam","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521277524?lang=en_us&edition=fundamental","pubTime":"2025-03-24 22:53","pubTimestamp":1742828000,"startTime":"0","endTime":"0","summary":"HS1 is used by Southeastern and Eurostar train services. A third operator seeking to challenge Eurostar’s monopoly on Channel Tunnel services has been announced.Gemini said on Monday it had submitted an application to the Office of Rail and Road  regulator for access to Eurostar’s Temple Mills depot, which is the only place in the UK to park and maintain high-speed, cross-Channel trains.Services will initially run between London and Paris/Brussels, but additional destinations are currently in the pipeline.The company, which is chaired by industry veteran Lord Tony Berkeley, said it had attracted a “highly experienced team of rail executives and creative thinkers” who are committed to bring open access services to the cross-channel route.","market":"fut","thumbnail":"https://www.cityam.com/wp-content/uploads/2024/07/0907-Eurostar-171115_Eurostar_Verbatim_149_R-e1722003847290.jpg?w=824&h=463&crop=1","type":0,"news_type":0,"thumbnails":["https://www.cityam.com/wp-content/uploads/2024/07/0907-Eurostar-171115_Eurostar_Verbatim_149_R-e1722003847290.jpg?w=824&h=463&crop=1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.cityam.com/third-eurostar-challenger-steps-up/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cityam_highlight","symbols":["ORR"],"gpt_icon":0},{"id":"2521940256","title":"Elevation Oncology Plunges 42% on Ending Development of Lead Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2521940256","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521940256?lang=en_us&edition=fundamental","pubTime":"2025-03-22 01:03","pubTimestamp":1742576580,"startTime":"0","endTime":"0","summary":"Shares of Elevation Oncology ELEV plunged more than 40% yesterday after reporting disappointing data from a phase I study on its lead pipeline drug EO-3021 for treating advanced, unresectable or metastatic gastric and gastroesophageal junction  cancers.Data from the study showed that patients who were treated with ELEV’s lead drug showed an objective response rate  of 22.2% —out of 36 evaluable patients, there was one complete response and seven partial responses.Following the disappointing study results, Elevation Oncology decided not to pursue further clinical development of EO-3021. Instead, the company will now shift its focus to solid tumor candidate EO-1022, for which an investigational new drug  filing with the FDA is expected next year. As a result of this decision, ELEV is now without a pipeline candidate in clinical development. These factors were likely responsible for the significant drop in share price.In the past 60 days, estimates for CytomX Therapeutics’ 2025 EPS have i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/elevation-oncology-plunges-42-ending-170300990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ORR","ANIP","CTMX","BK4585","ETNB","BK4139","BK4539","BK4007","ELEV"],"gpt_icon":0},{"id":"2521151496","title":"Press Release: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521151496","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521151496?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:05","pubTimestamp":1742501100,"startTime":"0","endTime":"0","summary":"-- Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S  in Acute Myeloid Leukemia  with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 --. -- Reported Positive Overall Survival and Overall Response Rate Data from the Ongoing Phase 2 Trial of SLS009  in r/r AML -- Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 --. Announced Positive Outcome of Interim Analysis for Phase 3 REGAL Trial of GPS in AML: The interim futility, efficacy, and safety analysis was designed to assess whether the therap","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","INN","ODD","LU1571399168.USD","BK4183","NCI","BK4533","BK4109","OS","R","BK4097","ASH","BK4139","SLS","BK4588","BK4181","BK4232","BK4585","ALL","CR","ORR","PR","BK4022","LU0985320562.USD","BK4213","LU1699723380.USD","LU2463526074.USD","BK4218","LU2355687059.USD","BK4107","BK4161"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":117,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{}}}